Krystal Biotech, Inc. (KRYS)

US — Healthcare Sector
Peers: CRSP  PCVX  PTCT  ARWR  TGTX  ALKS  MTSR  ACLX  PTGX  TFX 

Automate Your Wheel Strategy on KRYS

With Tiblio's Option Bot, you can configure your own wheel strategy including KRYS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KRYS
  • Rev/Share 12.8886
  • Book/Share 39.3008
  • PB 5.4734
  • Debt/Equity 0.0015
  • CurrentRatio 10.1421
  • ROIC 0.1126

 

  • MktCap 6237652225.0
  • FreeCF/Share 5.7192
  • PFCF 37.6699
  • PE 31.311
  • Debt/Assets 0.0014
  • DivYield 0
  • ROE 0.1936

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation KRYS Jefferies -- Buy -- $245 March 5, 2025

News

Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
KRYS
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive

KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.

Read More
image for news Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript
KRYS
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q4 2024 Results Conference Call February 19, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Suma Krishnan - President, Research and Development Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Ry Forseth - Guggenheim Josh Schimmer - Cantor Andrea Newkirk - Goldman Sachs Operator Thank you for standing …

Read More
image for news Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
KRYS
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023

Read More
image for news Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

About Krystal Biotech, Inc. (KRYS)

  • IPO Date 2017-09-20
  • Website https://www.krystalbio.com
  • Industry Biotechnology
  • CEO Krish S. Krishnan
  • Employees 275
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.